Neuronetics' $30 Million Offering Adds Shares Equal To About 19% Of The Post-Offering Total
Part of the money is intended to repay loans as the company seeks conditional relief from revenue requirements.
Neuronetics, which makes magnetic-stimulation systems for treating depression, priced a $30 million common-stock offering Tuesday at $1.60 a share, about 20% below Tuesday's $2.01 last reported sale price. The 18,750,000 new shares equal about 19% of the 96,478,311 shares outstanding after the offering, excluding the underwriters' option, according to its prospectus supplement filed Thursday.
Loan Relief Hinges On Prepayment
The stock sale would help Neuronetics repay a loan whose revenue requirements underpin an existing warning about its ability to keep operating. The company expects the conditional changes to those requirements would resolve that risk, it said in its pricing announcement.
Neuronetics owed $65 million under its Perceptive lending facility as of September 30, when the interest rate was 11.5%. The loans mature on July 25, 2029.
The company's projected revenue for the twelve months ending March 31, 2027, fell short of the minimum required under the earlier loan terms. That prompted a going-concern warning — substantial doubt about whether the company could continue operating.
A credit amendment signed November 5 would change certain revenue requirements once its conditions are met. Those include prepaying at least $15 million, plus accrued interest, applicable fees and lender costs. Neuronetics cautioned that satisfying the conditions and meeting the revised revenue minimum remain uncertain.
$27.7 Million After Costs
Neuronetics estimates it would receive $27.7 million after underwriting discounts and offering expenses. Its stated uses include “to repay a portion of the outstanding term loans under the Perceptive Facility” and “general corporate purposes,” according to the prospectus supplement.
William Blair, BTIG and Canaccord Genuity, the offering's underwriters, have a 30-day option from Tuesday's supplement date to buy up to 2,812,500 additional shares. Full exercise would bring estimated net proceeds to $31.9 million and post-offering shares outstanding to 99,290,811.
STIM shares stood at $1.62 at Wednesday's close.
Systems And Greenbrook Clinics
Neuronetics sells its NeuroStar Advanced Therapy System and recurring treatment sessions, mainly to U.S. psychiatrists. The office-based therapy uses non-invasive magnetic stimulation to target brain areas associated with mood.
The system has FDA clearance for major depressive disorder, as an additional treatment for adults with obsessive-compulsive disorder, and to reduce anxiety symptoms in adults with depression. It is also cleared for patients aged 15–21 with major depressive disorder.
Neuronetics bought Greenbrook in December 2024. As described in its 2025 annual report, it runs 93 Greenbrook treatment centers, with most revenue coming from clinics and treatment sessions. Revenue totaled $149.2 million for 2025.
The credit amendment automatically terminates unless its conditions are satisfied or waived by November 30.
Sources
- Form 424B5 — Neuronetics, Inc. (STIM) — SEC EDGAR
- Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common Stock | Morningstar — morningstar.com
- Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common Stock — Yahoo Finance
- Neuronetics Announces Pricing of $30 Million Underwritten — globenewswire.com
- Neuronetics Announces Proposed Public Offering of Common — globenewswire.com